Elbit Medical Imaging of Haifa, Israel, reported that sales in its Elbit Ultrasound unit were $182.4 million for its 1997 fiscal year (end-December), down 13% compared with revenues of $208.9 million in 1996. For the fourth quarter, the division had
Elbit Medical Imaging of Haifa, Israel, reported that sales in its Elbit Ultrasound unit were $182.4 million for its 1997 fiscal year (end-December), down 13% compared with revenues of $208.9 million in 1996. For the fourth quarter, the division had revenues of $58.6 million, compared with $63.6 million in the fourth quarter of 1996, a decline of 8%.
Elbit said the reduction in the ultrasound division's revenues was primarily due to the discontinuation of sales of Hitachi Ultrasound products, which Elbit Ultrasound distributed until December 1996. Sales of Hitachi products contributed $32 million to Elbit Ultrasound's revenues in 1996.
The ultrasound division is composed of Diasonics Vingmed Ultrasound, which Elbit has agreed to sell to GE Medical Systems (SCAN 3/4/98). Elbit said it continues to work on GE's proposal to acquire Diasonics Vingmed, and hopes to have a final agreement signed by the end of March.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.